Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Emanuele Pontali, Mario C. Raviglione, Giovanni Battista Migliori. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019

Member's Comments

No comment yet.

Related content which might interest you: Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges Source: Eur Respir J 2016; 48: 938-943 Year: 2016 A new era for treatment of drug-resistant tuberculosis Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018 Year: 2018 MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Two major problems in TB patients today: MDR and the abandoned therapy Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011 Multidrug-resistant tuberculosis around the world: what progress has been made? Source: Eur Respir J 2015; 45: 150-160 Year: 2015 Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 670-672 Year: 2016 Medico-surgical considerations when looking for treatment for multidrug-resistant TB Source: Eur Respir J 2002; 20: Suppl. 38, 361s Year: 2002 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 Extensively drug-resistant tuberculosis: back to the future Source: Eur Respir J 2010; 36: 475-477 Year: 2010 Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection Source: Eur Respir J 2010; 36: 1242-1247 Year: 2010 Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Source: Eur Respir J 2008; 31: 904-905 Year: 2008 Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated Source: Eur Respir J , 49 (3) 1700081; DOI: 10.1183/13993003.00081-2017 Year: 2017 Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review Source: Eur Respir J, 53 (1) 1801030; 10.1183/13993003.01030-2018 Year: 2019 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The global response to rifampicin-resistant tuberculosis: Current situation and recent trends Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016